{"database": "lobbying", "table": "lobbying_activities", "rows": [[3000277, "cd957248-35fe-4fc7-822e-ebb4eb8b94b8", "Q2", "IPOLICY SOLUTIONS", 401105127, "INVITAE INC.", 2023, "second_quarter", "MED", "H.R.2369 - VALID Act of 2023 FDA Guidance, Docket No. FDA-2022-D-2983 for Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products FDA public meeting, FDA-2018-N-4002 Electronic Submission of Adverse Event Reports to FAERS Using ICH E2B(R3) Standards FDA guidance, Docket No. FDA-2023-D-0110: Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 90000, null, 0, 0, "2023-07-10T10:03:38-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3000277"], "units": {}, "query_ms": 0.7161300163716078, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}